EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort

Tanya Ramadoss, Christian Palacios, Matthew Nichols, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A Tarhini, Evan J Wuthrick, Vernon K Sondak, Kenneth Y Tsai, Nikhil I Khushalani, Andrew S Brohl

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04313-2 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Tanya Ramadoss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL, USA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Barry S. Greene Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellIpilimumabNivolumabAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsHumansProspective StudiesImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Checkpoint inhibitorImmunotherapyIpilimumabMerkel cell carcinomaNivolumab

Substanzen

IpilimumabNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL, USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. andrew.brohl@moffitt.org.
  • Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA. andrew.brohl@moffitt.org.

Förderung

  • Barry S. Greene Fund

Zitieren

APA

Ramadoss, T., Palacios, C., Nichols, M., Eroglu, Z., Markowitz, J., Karapetyan, L., Tarhini, A. A., Wuthrick, E. J., Sondak, V. K., Tsai, K. Y., Khushalani, N. I., & Brohl, A. S. (2026). First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04313-2

Vancouver

Ramadoss T, Palacios C, Nichols M, Eroglu Z, Markowitz J, Karapetyan L, et al. First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04313-2

BibTeX
@article{Ramadoss2026,
  author = {Ramadoss, Tanya and Palacios, Christian and Nichols, Matthew and Eroglu, Zeynep and Markowitz, Joseph and Karapetyan, Lilit and Tarhini, Ahmad A and Wuthrick, Evan J and Sondak, Vernon K and Tsai, Kenneth Y and Khushalani, Nikhil I and Brohl, Andrew S},
  title = {First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04313-2}
}
Kostenlos starten →